Zacks: Brokerages Set $25.50 Price Target for Vapotherm Inc (VAPO)
Shares of Vapotherm Inc (NYSE:VAPO) have been assigned an average broker rating score of 1.00 (Strong Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy recommendation.
Analysts have set a one year consensus price objective of $25.50 for the company and are predicting that the company will post ($0.82) earnings per share for the current quarter, according to Zacks. Zacks has also given Vapotherm an industry rank of 153 out of 256 based on the ratings given to its competitors.
A number of analysts have recently commented on the company. Zacks Investment Research upgraded Vapotherm from a “sell” rating to a “hold” rating in a report on Friday, March 22nd. Canaccord Genuity boosted their price target on Vapotherm from $22.00 to $27.00 and gave the company a “buy” rating in a report on Wednesday, March 13th.
Vapotherm (NYSE:VAPO) last posted its earnings results on Tuesday, May 7th. The company reported ($0.76) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.03. The business had revenue of $12.30 million for the quarter, compared to the consensus estimate of $11.90 million. On average, analysts forecast that Vapotherm will post -3.15 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. American International Group Inc. bought a new stake in shares of Vapotherm in the fourth quarter valued at approximately $61,000. Advisor Group Inc. acquired a new position in Vapotherm in the first quarter valued at about $88,000. New York State Common Retirement Fund acquired a new position in Vapotherm in the fourth quarter valued at about $118,000. Deutsche Bank AG acquired a new stake in shares of Vapotherm during the fourth quarter worth about $121,000. Finally, Barclays PLC acquired a new stake in Vapotherm in the fourth quarter valued at approximately $142,000. 45.69% of the stock is currently owned by hedge funds and other institutional investors.
Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary Hi-VNI technology products used to treat patients of various ages suffering from respiratory distress worldwide. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that use Hi-VNI technology to deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.
Recommended Story: What is the Federal Reserve?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.